Amgen Inc. Receives Average 'Hold' Recommendation from Thirty Research Firms

Amgen Inc., a global biotechnology company, has been given an average recommendation of 'Hold' by thirty research firms covering the stock. Among those firms, two have assigned a sell rating, fifteen have a hold rating, eleven have a buy rating, and two have a strong buy rating.

The average 12-month price target among these brokerages is $357.00. In recent news, Amgen has been expanding its presence in the healthcare market, including its entry into type 2 diabetes with AMG 127.

However, the company faces challenges as it contends with a data breach involving patient health information and proprietary company data.